Troy Wilson, Ph.D., J.D.
About Troy Wilson, Ph.D., J.D.
Troy Wilson, Ph.D., J.D., is a distinguished leader in the biopharmaceutical industry, currently serving as the President and CEO of multiple bioscience companies and holding significant roles on various boards.
Troy Wilson, Ph.D., J.D. - Educational Background
Troy Wilson holds a Juris Doctor degree from New York University. He has also earned a Ph.D. in bioorganic chemistry and a Bachelor of Arts degree in biophysics from the University of California, Berkeley. This diverse educational foundation in both law and science has equipped him with a unique combination of skills and knowledge, applicable across various roles in the biotechnology sector.
Troy Wilson - Career at Avidity Biosciences
Troy Wilson has held key leadership roles at Avidity Biosciences, Inc., including serving as President and Chief Executive Officer from November 2012 to February 2019. He continues his involvement with the company as Chairman and a member of the Board of Directors since February 2019 and November 2012, respectively. His tenure has been marked by his strategic guidance and leadership.
Troy Wilson's Leadership at Wellspring Biosciences
From July 2012 to March 2019, Troy Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., and its parent company Araxes Pharma LLC. He remains actively involved with both entities as Executive Chairman and a member of the Board of Directors of Wellspring Biosciences since February 2019, and a member of the Board of Managers of Araxes Pharma LLC since July 2012.
Troy Wilson's Role in Puma Biotechnology
Since October 2013, Troy Wilson has been a member of the Board of Directors of Puma Biotechnology, Inc. His experience and leadership within the biotechnology sector support his contributions to the company's strategic direction and governance.
Previous Experience: Intellikine, Inc.
Troy Wilson served as President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., from April 2007 to January 2012. During his tenure, he guided the company through various phases of growth and development, leveraging his extensive background in both science and law.